Patent SG-11201907755P-A (SG)
Title: Anti-pd-l1-anti-tim-3 bispecific antibodies
Inventor: D'ANGELO IGOR EDMONDO PAOLO
IPC: A61P35/00
Filed: 2018-04-04
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) W I PO I PCT omit VIII °nolo mu oionmoimmo oimIE (10) International Publication Number WO 2018/191074 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/026060 (22) International Filing Date: 04 April 2018 (04.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/484,025 11 April 2017 (11.04.2017) US (71) Applicants: ELI LILLY AND COMPANY [US/US]; Lil- ly Corporate Center, Indianapolis, Indiana 46285 (US). ZYMEWORKS INC. [CA/CA]; 540-1385 West 8th Av- enue, Vancouver, British Columbia V6H 3V9 (CA). (72) Inventors: D'ANGELO, Igor Edmondo Paolo; c/o ZYMEWORKS INC., 540-1385 West 8th Avenue, Van- couver, British Columbia V6H 3V9 (CA). LI, Yiwen; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapo- lis, Indiana 46206-6288 (US). LUDWIG, Dale Lincoln; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indi- anapolis, Indiana 46206-6288 (US). SHEN, Yang; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). ZHANG, Yi; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (74) Agent: JOHNSON, Robert B. et al.; ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). — (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 1-1 O \" (57) : The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human TIM-3, and may 0 be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics. (54) Title: ANTI-PD-LI-ANTI-TIM-3 BISPECIFIC ANTIBODIES